Local control in metastatic neuroblastoma in children over 1 year of age

Maria Antonietta De Ioris1*, Alessandro Crocoli2, Benedetta Contoli1, Maria Carmen Garganese3, Gianluigi Natali3, Paolo Tomà3, Alessandro Jenkner1, Renata Boldrini4, Maria Debora De Pasquale3, Giuseppe Maria Milano1, Silvia Madafferi2, Aurora Castellano1, Franco Locatelli1,5 and Alessandro Inserra2

Abstract

Background: Local control is always considered in metastatic neuroblastoma (NBL). The aim of this study is to evaluate the impact of radical surgery on survival in children over 1 year of age.

Methods: Fifty-eight patients older than 1 year of age with metastatic NBL were treated with conventional plus high-dose chemotherapy with or without addition of local radiotherapy (RT, 21Gy). Surgery was classified as radical surgery (complete resection and gross total resection) or non-radical surgery. The Kaplan-Meier method and the Cox proportional hazard model were used to calculate the probability of progression free and overall survival (PFS and OS) and for multivariate analysis.

Results: The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%) respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI 10-55%) (respectively, P 0.85 and P 0.42). The 5-year PFS and OS for patients who received RT were 36% (95% CI 19-53%) and 46% (95% CI 26-64%) respectively, while the 5-year PFS and OS for patients who did not receive RT were 22% (95% CI 9-38%) and 27% (95% CI 13-42%) respectively (P 0.02 for PFS). Multivariate analysis confirmed the role of well-known prognostic factors, such as the presence of MYCN amplification, age and response before high-dose chemotherapy.

Conclusions: Our data suggest that the degree of resection does not influence survival in metastatic NBL patients treated with high-dose chemotherapy; local RT contributes to local disease control.

Keywords: Neuroblastoma, Surgery, Metastasis, Radiotherapy, Prognosis

Background

Neuroblastoma (NBL) is the most common solid extra-cranial tumor of childhood. The clinical course varies from spontaneous tumor regression to an aggressive, poorly responding disease, depending on patient age at diagnosis, metastatic dissemination and MYCN status [1]. Despite intensive treatment, the outcome of high-risk NBL (i.e. metastatic disease or patients with MYCN amplification) remains unsatisfactory: the reported 3-year event-free survival (EFS) is less than 40% in many studies [1-6]. Currently, standard treatment for high-risk NBL is based on intensive systemic chemotherapy, surgery on primary tumor, high-dose chemotherapy followed by autologous bone marrow transplantation (ABMT) and/or peripheral blood stem cell transplantation (PBSC), radiotherapy (RT) on primary tumor bed and differentiating/immunotherapy treatment [1-6]. Local control of NBL, based on surgery and RT on primary site, is considered a valuable option in most international protocols. Nevertheless, the impact of surgery on survival in metastatic NBL treated with an intensive approach remains controversial [7-15]. Some authors reported a favorable outcome in patients who undergo gross total resection (i.e. >95%) of the primary tumor [7-11]; others failed to show an improvement in survival rate after radical surgical excision [12-15]. However, several studies suggested that RT contributes significantly to the prevention of local relapse [16-18].

© 2015 De Ioris et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The aim of this study was to analyze the role of surgery in a series of metastatic NBL in children over 1 year of age diagnosed and treated at the Ospedale Pediatrico Bambino Gesù (OPBG). All patients were treated according to two previously published local protocols based on conventional chemotherapy followed by high-dose chemotherapy [19-21].

**Methods**

Children over one year of age with metastatic NBL were classified as having high-risk disease and were enrolled in two consecutive institutional protocols from July 1996 to August 2009. The first protocol was identified as ICE/CECAT [18] and the second as TopoNB [19]. The ICE/CECAT protocol consisted of two courses of ifosfamide/carboplatin/etoposide (ICE), two courses of cyclophosphamide/etoposide/carboplatin/thiotepa (CECAT) or two further ICE courses.

The Topo/NB protocol consisted of two courses of topotecan/cyclophosphamide followed by two courses of ifosfamide/carboplatin/etoposide (ICE) and a later course of cyclophosphamide/doxorubicin/vincristine. The Ethical Committee of Ospedale Pediatrico Bambino Gesù IRCCS (ref number 62,10; May, 17th 2010) approved both protocols, as well as this retrospective study. Written informed consent was obtained from the children or parents or legal guardians. Both protocols were based on conventional induction chemotherapy, surgery on primary tumor and high-dose chemotherapy followed by PBSC rescue and/or ABMT plus 9-cis retinoic acid as previously reported [18-21]. In the second and more recent protocol, the treatment was completed by local RT with 21 Gy on tumor bed before surgery [17].

Surgical resection of primary tumor was performed either at diagnosis or after the 4th or 5th course of chemotherapy. In detail, patients with tumors considered to be resectable at diagnosis underwent primary surgery, while patients with unresectable tumor at diagnosis and without disease progression after induction chemotherapy underwent delayed surgery.

The same surgical team performed the surgery in all patients. The surgical and pathology reports and imaging before and after surgery, were reviewed for this study. Surgery was classified as “radical” or “not radical”. The “radical” group included patients who had undergone complete resection with no visible tumor or at least a gross total resection (GTR) with less than 5% of visible tumor. The “not radical” group included patients who had undergone a partial resection (PR) with more than 50% tumor volume removal or biopsy only.

**Evaluation of disease**

Primary tumor evaluation was done by computed tomography (CT) or magnetic resonance imaging (MRI). Metastatic spread was assessed by total body CT scan and 123-iodine metaiodobenzylguanidine (123I-MIBG) scintigraphy and completed by two bilateral trephines and bone marrow aspirates. Diagnosis and staging were performed according to the International Neuroblastoma Diagnosis and Staging Criteria [22]. Primary tumor response was evaluated using the same investigations as those employed at diagnosis. Responses were assessed according to the International Neuroblastoma Response Criteria [22].

**Statistical analysis**

Progression-free survival (PFS) was defined as the time interval from the date of diagnosis to the date of first relapse/progression or the date of the last follow-up for surviving patients. Overall survival (OS) was defined as the time interval between the date of diagnosis and the date of death from any cause or the date of last follow-up for surviving patients. Local progression-free survival (LPFS) was defined as the time interval between the date of diagnosis and the date of first local relapse/progression or the date of the last follow-up. The Kaplan–Meier method was used to estimate survival curves [23], while the log-rank test was used to compare differences between groups. Multivariate analyses were performed using Cox proportional hazards regression model for PFS and OS. All variables with P values >0.2 in univariate analysis were included in the initial model and were then eliminated one at a time in a stepwise fashion to retain only those variables that reached a P value of 0.05 or less in the final models. All P values were 2-sided, with a type-I error rate fixed at 0.05. Variables considered as potentially influencing PFS and OS were: age (either >18 months or <18 months), site of primary tumor, site of metastasis (bone/bone marrow/lymph node or lymph node alone or others), MYCN status (MYCN amplified versus MYCN non amplified or MYCN gain), induction regimen, response before surgery, RT, response at the end of induction and quality of surgery, defined as radical or non-radical surgery. Analyses were performed using the Stata 9.0 statistical software package (StataCorp LP, TX, USA).

**Results**

This study evaluated 58 children over one year of age diagnosed with metastatic NBL at the OPBG and enrolled into two local treatment protocols. Patient characteristics are summarized in Table 1. Median age at diagnosis was 36 months (range 13–216), 11 of the 58 patients (19%) being younger than 18 months. Surgery was performed at diagnosis in 7 patients and was radical in 6 of them. In 47 (81%) patients tumor resection was performed after induction chemotherapy and was complete in 39 (83%). MYCN status was available for 56 patients;
out of 43 patients with radical surgery, 13 presented MYCN amplification while 6 patients out of 13 without radical surgery had MYCN amplification (P 0.29).

In this series, there was no intraoperative death; one patient died after surgery due to acute renal failure. Nephrectomy was performed in 7 patients (13%), polar nephrectomy for renal NBL and partial liver removal in one patient each. Post-surgery abscess, massive blood loss (defined as loss of one blood volume in 24 hours, or 50% loss of one blood volume in 3 hours, or losses over 1,45 ml/kg/min for 20 minutes, or transfusion of over > 40 ml/kg of red cells) [24,25], or the need for mechanical ventilation for more than 5 days were not recorded.

### Table 1 Patient characteristics

| Characteristic                        | N  | %  |
|--------------------------------------|----|----|
| **Age**                              |    |    |
| Median (months)                       | 36 |    |
| Range (months)                        | 13-216 | |
| **Gender**                           |    |    |
| Male                                 | 35 | 60 |
| Female                               | 23 | 40 |
| **Site of Metastasis**               |    |    |
| Bone/Bone Marrow/ Lymph node         | 48 | 83 |
| Lymph node alone                     | 3  | 5  |
| Others                               | 7  | 12 |
| **Primary Sites**                    |    |    |
| Retroperitoneal                      | 12 | 21 |
| Adrenal Gland                        | 41 | 71 |
| Thorax                               | 5  | 8  |
| **MYCN** (available for 56 pt)       |    |    |
| Amplified                            | 19 | 34 |
| Non amplified or MYCN gain           | 37 | 66 |
| **Induction CT**                     |    |    |
| ICE/CECAT                            | 21 | 36 |
| Topo NB                              | 37 | 64 |
| **Primary Tumor Reduction before Surgery** | 7 | 8 |
| <50%                                 | 4  |    |
| >50%, <95%                           | 34 | 68 |
| >95%                                 | 12 | 24 |
| **Surgery**                          |    |    |
| Radical                              | 45 | 78 |
| Not Radical                          | 13 | 22 |
| **Response before HDC**              |    |    |
| CR/VGPR                              | 21 | 37 |
| PD                                   | 11 | 20 |
| PR                                   | 24 | 43 |
| **RT**                               |    |    |
| Yes                                  | 28 | 48 |
| No                                   | 30 | 52 |

LEGEND: pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response. For “others” site of metastasis was considered Bone or/and Bone Marrow or/and Lymph node plus lung or/and liver metastasis.

*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.

**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.

### Survival

The median follow-up for the entire cohort was 45 months (range 1 month-16 years). The 5-year PFS and OS were 28% (95% CI 17-40%) and 36% (95% CI 24-49%), respectively, while the 5-year LPFS was 72% (CI 25-83%). Out of 58 patients, 41 (71%) died at a median time from diagnosis of 28 months (range 1–94 months); 39 died due to relapsed/resistant disease and two from complications (the patient who died of renal failure after surgery and one who died due to acute bleeding after accidental removal of the central venous catheter). Relapse/progression occurred in 39/58 (67%) patients after a median time from diagnosis of 15 months (range 6–49 months). Local relapse occurred in 12/58 (20%) patients; none of them had received RT, while radical surgery had been performed in 10 of the 12 patients. Local relapse was observed in 7 out of 19 (37%) patients with MYCN-amplified tumor, while relapses were recorded in only 5 out of 37 (14%) patients with non-MYCN-amplified tumors (P < 0.005). The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%) respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI 10-55%) (P 0.85 for PFS and P 0.42 for OS, (Figures 1 and 2). The 5-year PFS and OS for patients who did or did not receive RT were 36 % (95% CI 19-53%) and 46% (95% CI 26-64%) respectively, and 22% (95% CI 9-38%) and 27% (95% CI 13-43%) respectively (P < 0.02 for PFS and P = 0.23 for OS).

On univariate analysis, age, site of metastasis, MYCN status, response before high-dose chemotherapy and RT were factors influencing patient outcome (See Table 2 for more details). The final model of the multivariate analysis showed age, MYCN status and response before high-dose chemotherapy to be prognostic factors for
PFS and OS. MYCN amplification was associated with poor OS (HR 2.24, P = 0.043) as 183 were age >18 months (HR 4.52, P = 0.042) and Progressive Disease (PD) at the end of induction (HR 5.75, P < 0.001). Moreover, in this series RT was a protective factor for OS; patients who did not receive RT presented an HR of 2.36 (P = 0.025) for OS. Response before high-dose chemotherapy was shown to be the major prognostic factor for PFS; patients with PR presented an HR of 3.15, P = 0.006. Regarding LPFS, response before high-dose chemotherapy, RT and MYCN status were found to be the major prognostic factors. The 5-year LPFS in patients who did or did not receive RT was 100% and 48% (95% CI 27-67%) respectively (P <0.001) (see also Table 3 for more details). In the final model of multivariate analysis, MYCN amplification was shown to be a prognostic factor for local recurrence with an HR of 2.16 and P = 0.043.

**Table 2 Univariate analysis of outcome’s predictive factors**

|                  | Pts | PFS 5 years | 95% CI | Univariate analysis | P value | OS 5 years | 95% CI | Univariate analysis | P value |
|------------------|-----|-------------|--------|---------------------|---------|------------|--------|---------------------|---------|
| **Age**          |     |             |        |                     |         |            |        |                     |         |
| 12-18 months     | 11  | 64          | 30-85  | 0.01                |         | 73         | 37-90  | 0.03                |         |
| >18 months       | 47  | 19          | 9-32   | 28                  |         | 28         | 16-41  |         |         |
| **Site of Metastasis** |      |             |        |                     |         |            |        |                     |         |
| Bone/Bone Marrow/Lymph-node | 48  | 25          | 14-39  | 0.03                |         | 35         | 22-49  | 0.03                |         |
| Lymph-node alone | 3   | 100         | -      | 100                 |         | 100        | -      |         |         |
| Others           | 7   | 14          | 1-46   | 14                  |         | 1-46       | 1-46   |         |         |
| **Primary Sites** |     |             |        |                     |         |            |        |                     |         |
| Retroperitoneal   | 12  | 17          | 3-41   | 0.28                |         | 11         | 1-38   | 0.21                |         |
| Adrenal Gland     | 41  | 28          | 15-42  | 40                  |         | 25         | 25-55  |         |         |
| Thorax            | 5   | 60          | 13-88  | 60                  |         | 13         | 13-88  |         |         |
| **MYCN**          |     |             |        |                     |         |            |        |                     |         |
| Amplified (available for 56 pt) | 19  | 30          | 11-52  | 0.24                |         | 26         | 10-47  | 0.00                |         |
| Non amplified or MYCN gain | 37 | 29          | 16-44  | 44                  |         | 27         | 27-59  |         |         |
| **Induction CT**  |     |             |        |                     |         |            |        |                     |         |
| ICE/CECAT         | 21  | 20          | 6-39   | 0.59                |         | 29         | 12-48  | 0.19                |         |
| Topo NB           | 37  | 33          | 19-49  | 40                  |         | 24         | 24-56  |         |         |
| **Primary Tumor Reduction before Surgery** |     |             |        |                     |         |            |        |                     |         |
| <50%              | 35  | 22          | 9-38   | 0.52                |         | 38         | 21-54  | 0.43                |         |
| >50%, <90%        | 4   | 0           | -      | 0                   |         | 0          | -      |         |         |
| >90%              | 12  | 33          | 10-59  | 33                  |         | 10         | 10-59  |         |         |
| **Surgery**       |     |             |        |                     |         |            |        |                     |         |
| Radical           | 45  | 26          | 14-40  | 0.85                |         | 38         | 23-52  | 0.42                |         |
| Not Radical       | 13  | 33          | 10-59  | 31                  |         | 10         | 10-59  |         |         |
| **Response before HDC** |     |             |        |                     |         |            |        |                     |         |
| CR/VGPR           | 21  | 62          | 38-79  | <0.001              | 65      | 40-82      | <0.001 |         |         |
| PD                | 11  | 0           | -      | 10                  |         | 1-33       |       |         |         |
| PR                | 24  | 13          | 3-29   | 29                  |         | 13-48      |       |         |         |
| **RT**            |     |             |        |                     |         |            |        |                     |         |
| Yes               | 28  | 36          | 19-53  | 0.23                | 46      | 26-64      | 0.02   |         |         |
| No                | 30  | 22          | 9-38   | 27                  |         | 13-43      |       |         |         |

**LEGEND:** pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response.

*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.

**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.

Progression-Free Survival and Overall Survival according to predictive factors.
Discussion

Treatment of metastatic NBL in children over 1 year of age continues to represent a challenge for pediatric oncologists. Local control is always considered in the therapeutic strategy for children with metastatic NBL; however, its role in the treatment of patients receiving high-dose chemotherapy remains a subject of medical debate [26]. In this series of homogeneously treated metastatic NBL, the quality of surgery had no impact on survival. Indeed, the PFS and OS of patients who underwent radical surgery were comparable with those of patients with partial removal of primary tumor or biopsy only. Multivariate analysis showed that previously identified prognostic factors, i.e. MYCN amplification, age at diagnosis and response at the end of the induction phase, represented the major prognostic factors in the patient cohort.

This is the first single-center report on the impact of local control in terms of survival in patients treated with high-dose chemotherapy and conventional therapy, or with different post-induction treatments [7-15].

There are still conflicting reports in the literature concerning the role of radical surgery [26]. Some Authors reported the absence of any advantage in terms of survival probability for patients with CR of the primary tumor, as it is almost impossible to achieve a complete absence of microscopic residual disease on the tumor bed [27]. However, in a single center study analyzing cases diagnosed over more than 20 years, LaQuaglia et al. noted that gross tumor resection correlated with an improved outcome in terms of both local control and OS [8]. In a single center study, McGregor et al. observed an advantage for gross total resection in terms of survival [11]. In both these series [8,11], patients received different post-induction treatments.

Adkins et al. [9] showed a trend toward improved survival for complete resection in high risk NBL treated according to the CCG-3891 study. This study included metastatic patients over 1 year of age and patients with localized MYCN-amplified tumor. The randomized CCG-

---

Table 3 Univariate analysis of factors predictive for Local PFS

|                      | Pts | Local PFS % | 95% CI          | Univariate analysis |
|----------------------|-----|-------------|-----------------|---------------------|
| **Age**              |     |             |                 |                     |
| 12-18 months         | 11  | 100         | -               | 0.04                |
| >18 months           | 47  | 63          | 42-76           |                     |
| **Site of Metastasis**|    |             |                 |                     |
| Bone /Bone Marrow/ Lymph-node | 48  | 75          | 56-86           | 0.07                |
| Lymph-node alone     | 3   | 100         | -               |                     |
| Others               | 7   | 27          | 1-69            |                     |
| **Primary Sites**    |     |             |                 |                     |
| Retroperitoneal      | 12  | 59          | 16-86           | 0.50                |
| Adrenal Gland        | 41  | 76          | 55-88           |                     |
| Thorax               | 5   | 60          | 13-88           |                     |
| **MYCN**             |     |             |                 |                     |
| (available for 56 pt)|    |             |                 |                     |
| Amplified            | 19  | 51          | 23-74           | 0.00                |
| Non-amplified or MYCN gain | 37  | 80          | 59-91           |                     |
| **Induction CT**     |     |             |                 |                     |
| ICE/CECAT            | 21  | 55          | 28-76           | 0.12                |
| Topo NB              | 37  | 83          | 53-93           |                     |
| **Primary Tumor Reduction before Surgery** | | | | |
| <50%                 | 35  | 78          | 54-90           | 0.04                |
| >50%, <90%           | 4   | 50          | 1-91            |                     |
| >90%                 | 12  | 47          | 17-72           |                     |
| **Surgery**          |     |             |                 |                     |
| Radical              | 45  | 68          | 49-81           | 0.35                |
| Not Radical          | 13  | 90          | 47-99           |                     |
| **Response before HDC** |   |             |                 |                     |
| CR/VGPR              | 21  | 86          | 62-95           | <0.001              |
| PD                   | 11  | 0           | -               |                     |
| PR                   | 24  | 64          | 34-83           |                     |
| **RT**               |     |             |                 |                     |
| Yes                  | 28  | 100         | -               | <0.001              |
| No                   | 30  | 48          | 27-67           |                     |

**LEGEND:** pt, patient; BX, biopsy; CR, complete remission; VGPR, very good partial remission; PD, progressive disease; PR, partial response.

*In 7 patients surgery was performed at diagnosis, one patient died for an acute bleeding after accidental removal of central vein catheter.

**Two patients were not considered for this analysis; one patient died for acute bleeding and the later one died for acute renal failure.
3891 study compared high-dose chemotherapy followed by ABMT with maintenance chemotherapy [3]. Recently, Simon et al. [15] reported no impact of primary tumor surgery on local control and survival in 278 cases of metastatic NBL diagnosed in children over 18 months of age, enrolled in the German clinical trial NB97 and with no progression, relapse or death during the first 120 days of induction chemotherapy. This study was a randomized trial comparing high-dose chemotherapy followed by ABMT with oral maintenance chemotherapy [4,14].

In this paper, the authors discuss whether a single-center study or a multi-center study is the best setting for evaluating the impact of surgery in metastatic NBL. Probably, the single center series is more suitable for this analysis since, in such studies, all the procedures are performed by the same highly trained surgeons, thus avoiding a “different degrees of surgeons’ expertise” bias. Although the number of patients enrolled in our study was limited, the data clearly suggest that the type of surgery has no impact in terms of survival in metastatic NBL in children over one year of age treated with high-dose chemotherapy.

In this series, primary surgery was performed in about 10% of patients, achieving in most cases a CR of primary tumor, whereas, after the induction phase, surgery was performed in more than 90% of patients. Overall, radical surgery was performed in 80% of patients. Nephrectomy – recorded in 13% of patients - was the major complication. The International Neuroblastoma Risk Group modified the criteria for classification of localized NBL, including the image-defined risk factors (IDRFs), which assess both the staging of the tumor and the criteria for identifying and predicting the surgical risks for vital structures [27,28]. IDRFs could be a useful tool for the surgeon, even for patients with metastatic high-risk NBL, in that they predict and possibly help to avoid both acute and late surgical complications such as renal failure after nephrectomy, renal atrophy after adrenal resection, and ejaculatory dysfunction secondary to pelvic resection. In this series, the same surgical team performed both the pre-surgical patient evaluation and the surgical procedure. The involvement of a highly-experienced surgical team will probably result in a lower rate of post-operative complications, even in patients with several surgical risk factors. As underlined by Simon [15], surgery should be conservative and the risk of removing the kidney or any other vital organ should be carefully weighed against any potential benefits.

As previously reported, RT after surgery seems the best option to control local relapse [16–18]. Our findings confirm these previously published data since, in this cohort, RT was associated with a lower local recurrence rate. Indeed, the LPFS in patients who received RT was 100% and contributed to improving the probability of OS considering that patients who did not receive RT had an HR of 2.36 for OS (P = 0.025).

Conclusions
In conclusion, we show that the extent of surgery had no impact on survival in a our single center series of homogeneously treated metastatic NBL. Surgery may help to achieve the best disease control before high-dose chemotherapy and should be proposed to all patients after the induction phase; in centers with experienced surgeons, it could be discussed at diagnosis after considering the IDRFs.

Competing interests
The authors declare that they have no competing interests.
This study was presented in part at the SIOP Annual Meeting 2012.

Authors’ contributions
MADI and AC contributed equally to the work, performing study design, revising collected data, drafting and finalizing the manuscript. BC performed all CT and MRI scans revision, collecting all the related data about study population. GN and PT performed all CT and MRI scans revision, collecting all radiological data about study population. AJ, MDDP, GMM, SM and AC revised all clinical and surgical data, collecting them in a database, also performing critical revision of final manuscript before the submission. RB performed all reviews of both pathological specimens and reports. FL and AI contributed equally to the work, performing study design, revising and approving final manuscript. All authors read and approved the final manuscript.

Funding
This work was partially supported by grants awarded by the Associazione Italiana per la Ricerca sul Cancro (AIRC) n.9962 and by the Ministero dell’Istruzione, dell’Università e della Ricerca (Grant Progetto di Rilevante Interesse Nazionale 2010) to FL.

Author details
1Hematology/Oncology Department, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy. 2Surgery Department, Rome, Italy. 3Imaging Department, Rome, Italy. 4Pathology Department, Bambino Gesù Children’s Hospital, Rome, Italy. 5University of Pavia, Pavia, Italy.

Received: 29 August 2014 Accepted: 11 February 2015
Published online: 21 February 2015

References
1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Advances in the diagnosis 280
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.
3. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:498–505.
4. Pritchard J, Cotterill SJ, Germond SM, I meson J, De Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European neuroblastoma study group. Pediatr Blood Cancer. 2005;44:348–57.
5. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children’s oncology group study. J Clin Oncol. 2009;27:1007–13.
6. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study Group; Children’s Cancer and Leukaemia Group (CCLG formerly United Kingdom Children’s Cancer Study Group).
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–56.

7. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsay KL, Cheung NK. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg. 1994;29:1162–5.

8. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004;39:412–7.

9. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children’s Cancer Group study. J Pediatr Surg. 2004;39:931–6.

10. Koh CC, Sheu JC, Liang DC, Chen SH, Liu HC. Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma. Pediatr Surg Int. 2005;21:69–72.

11. McGregor LM, Rao BN, Davidson AM, Billups CA, Hongeng S, Santana VM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children’s research hospital experience. Cancer. 2005;104:2837–46.

12. Von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg. 2002;12:402–9.

13. Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg. 2002;37:1574–8.

14. Sultan I, Ghandour K, Al-Jumaily U, Hashem S, Rodriguez-Galindo C. Local control of the primary tumour in metastatic neuroblastoma. Eur J Cancer. 2009;45:1728–32.

15. Simon T, Häberle B, von Hero B, Schweinitz D, Berthold F. Role of surgery in the treatment of patients with stage 4 neuroblastoma Age 18 months or older at diagnosis. J Clin Oncol. 2013;31:752–8.

16. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28–39.

17. Watkins A, Wu J, Santana VM, Furman WL, Davidson AM, McGregor LM. Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children’s Research Hospital experience. J Pediatr Surg. 2010;45:678–86.

18. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001;19:2821–8.

19. Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl. 2004;93:6–11.

20. De Ioris MA, Castellano A, Ilari I, Garganese MC, Natali G, Insiena A, et al. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur J Cancer. 2011;47:572–8.

21. De Ioris MA, Contoli B, Jenkner A, De Pasquale MD, Serra A, DE Sio L, et al. Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. Anticancer Res. 2012;32:527–33.

22. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–77.

23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457–81.

24. British Committee For Standards in Haematology, Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ. Guidelines on the management of massive blood loss. Br J Hematol. 2006;135:634–1.

25. Giraldo MZ. Pediatric Perioperative Bleeding - basic consideration. Rev Colomb Anestesiol. 2013;41(1):44–9.

26. Zwaveling S, Tytgat GA, van der Zee DC, Wijnen MH, Heij HA. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may 95% tumour resection suffice? Pediatr Surg Int. 2012;28:953–9.

27. Monclair T, Brodeur GM, INRG Task Force, Ambros PF, Risse HJ, Cecchetto G, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:300–8.

28. Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNBSG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–9.